The study has read out. The evidence is not finished.
Gain a deeper understanding of your completed study by contextualizing the population, endpoints, and variability, and turn those insights into better-informed clinical development decisions.
How It Works
See how teams design, compare, and align on trial planning decisions earlier
- 01Explore trial precedent, observed data, and simulations in a single environment
- 02Compare endpoints, eligibility criteria, and design scenarios without building custom analyses
- 03See how protocol choices change populations and expected outcomes
- 04Iterate on design decisions live and understand trade-offs in real time
- 05Preserve assumptions, evidence, and results so rationale doesn’t disappear after meetings
Evidence for a smaller, faster Phase 3 in Alzheimer's
AbbVie applied Unlearn's digital twins to their completed Phase 2 AWARE study (NCT02880956), a randomized, double-blind, placebo-controlled trial in early AD assessing CDR-SB at Week 96. Result: a 17% sample-size reduction with 90% power maintained, without compromising Type-1 error control.In Alzheimer's program planning, retrospective analyses project Phase 3 savings of ~$50M–$70M and 4–5+ months per program.
THE LIFECYCLE
Readout informs the next design.
What this study revealed becomes evidence for the decision that follows readout, whether and how the program continues: a validated view of disease progression, a better estimate of the effect, and a design that starts from what you now know.
